Dactolisib - Novartis

Drug Profile

Dactolisib - Novartis

Alternative Names: BEZ-235; Dactolisib-tosylate; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX; RTB-101

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis; resTORbio
  • Class 3-ring heterocyclic compounds; Acetonitriles; Antineoplastics; Antivirals; Benzenesulfonates; Imidazoles; Nitriles; Quinolines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; 3 phosphoinositide dependent protein kinase 1 inhibitors; Apoptosis stimulants; Immunostimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections; Respiratory tract infections
  • Discontinued Breast cancer; Glioblastoma; Haematological malignancies; Non-small cell lung cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 25 Jul 2018 Adverse events and efficacy data from a phase IIb trial in Respiratory tract infections released by resTORbio
  • 11 Jul 2018 Efficacy data from a phase IIa trial in volunteers released by resTORbio
  • 22 Feb 2018 resTORbio plans a phase II clinical trial for Respiratory tract infections and Influenza virus infections (Combination therapy) in New Zealand in April 2018 (ACTRN12618000365268p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top